Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 5/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HTR1A | P08908 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215081 | 1.00 | HTR7 (0.41) | HTR7TRPA1LMNASMN1; SMN2HTR1A | |
| SCHEMBL12435190 | 0.89 | ALDH1A1 (0.40) | LMNAMAPT | |
| SCHEMBL16900674 | 0.78 | TRPA1 (0.46) | HTR7TRPA1LMNASMN1; SMN2HTR1A | |
| SCHEMBL16220192 | 0.74 | PSEN1 (0.50) | HTR7HTR1ATP53 | |
| SCHEMBL2185773 | 0.74 | CYP3A4 (0.48) | HTR7TRPA1LMNAHTR1ACYP3A4 | |
| SCHEMBL2185769 | 0.74 | CYP3A4 (0.48) | HTR7TRPA1LMNAHTR1ACYP3A4 | |
| SCHEMBL15494285 | 0.71 | — | — | |
| SCHEMBL18988641 | 0.71 | TRPA1 (0.46) | HTR7TRPA1LMNAHTR1ACYP3A4 | |
| SCHEMBL7118504 | 0.70 | MAPT (0.52) | HTR7TRPA1LMNASMN1; SMN2HTR1A | |
| SCHEMBL7118507 | 0.70 | MAPT (0.52) | HTR7TRPA1LMNASMN1; SMN2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637671-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2014-01-28 | — | — | US | disclosed |
| US-8637671-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2014-01-28 | — | — | US | disclosed |
| US-20110172263-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172263-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, PTGDR | HTR7 219/4885TRPA1 483/4885LMNA 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.